腹腔内侵袭性纤维瘤病临床治疗回顾

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (520 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical characteristics, treatment and prognosis of intraperitoneal aggressive fibromatosis. Methods The clinical data of 26 patients with intraperitoneal aggressive fibromatosis in Renmin Hospital of Wuhan University from January 2007 to June 2017 were analyzed retrospectively. All patients were confirmed by pathological diagnosis. The survival rate was analyzed between the patients undergoing radical surgery and those only undergoing radiotherapy or chemotherapy, and the survival curve was drawn by Kaplan-Meier method for the group with the tumor diameter larger than 10 cm(8 cases) and the group with the tumor diameter less than 10 cm(18 cases) respectively. The survival rate of two groups were compared with χ2 test and the survival curve was tested by Log-rank test. Results All the 26 patients were examined by CT or MRI before operation, only 1 case was considered as intraperitoneal aggressive fibromatosis. Among 22 patients who underwent radical resection, only 1 case dead in follow-up period, the overall survival rate was 95.45%; among 4 patients who only accepted radiotherapy or chemotherapy, 3 cases dead in follow-up period, overall survival rate was 25.00%, the difference in overall survival rate between the two groups was highly statistically significant (P ＜ 0.01). There was significant prognosis difference between the groups of tumor diameter larger than 10 cm and less than 10 cm (P = 0.033). Conclusion Intraperitoneal aggressive fibromatosis is difficult to diagnose before operation. Whether surgical treatment is the first choice, whether to perform radical resection and tumor size are the key factors affecting prognosis.

Key words： Intraperitoneal aggressive fibromatosis Surgery Tumor size Prognosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Hongxue ZOU Li KE Dong TONG Shilun

Cite this article:

WU Hongxue ZOU Li KE Dong TONG Shilun. Clinical treatment review of intraperitoneal aggressive fibromatosis[J]. 中国医药导报, 2018, 15(35): 106-109.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I35/106

[1] Ibrahim M，Sandogji H，Allam A. Huge intrathoracic desmoid tumor [J]. Ann Thorac Med，2009，4（3）：146-148.
[2] Mac Farlane J. Clinical Reports on the Surgical Practice of the Glasgow Royal Infirmary [M]. 5th ed. Glasgow：Glasgow Royal Infirmary，1832：63-66.
[3] Muller J. Ueber den Feineren Bau und Die Formen der Krankhaften Geschwulste [M]. Berlin：G Reimer，1838：60.
[4] 王坚.软组织肿瘤病理学[M].北京：人民卫生出版社，2008：113-117.
[5] van Broekhoven DL，Grunhagen DJ，den Bakker MA，et al. Time trends in the incidence and treatment of extra abdominal aggressive fibromatosis：a population-based study [J]. Ann Surg oncol，2015，22（9）：2817-2823.
[6] Kriz J，Eich HT，Haverkamp U，et al. Radiotherapy is effective for desmoid tumors aggressive fibromatosis long term results of a German multicenter study [J]. Oncol Res Treat，2014，37（5）：255-260.
[7] Fujishima T，Yoshida H，Obi S，et al. Analysis of factors influencing hepatocellular carcinoma detection：efficient use of computed tomography during arterial portography and during hepatic arteriography [J]. J Gastroenterol，2005， 40（3）：266-273.
[8] Martin D，Muradbegovic M，Andrejevic-Blant S，et al. Omental fibromatoss treated by laparoscopic wide surgical resection [J]. Intractable Rare Dis Res，2018，7（1）：51-53.
[9] Smith K，Desai J，Lazarakis S，et al. Systematic Review of Clinical Outcomes Following Various Treatment Options for Patients with Extra abdominal Desmoid Tumors [J]. Ann Surg Oncol，2018，25（6）：1544-1554.
[10] Hajjar WM，AlShehri AF，Alessa MA，et al. Late Presentation of Aggressive Fibromatosis Involving Head，Neck and Chest Wall [J]. J Coll Physicians Surg Pak，2017，27（10）：654-656.
[11] Eastley N，McCulloch T，Esler C，et al. Extra abdominal desmoid fibromatosis：A review of management，current guidance and unanswered questions [J]. Eur J Surg Oncol，2016，42（7）：1071-1083．
[12] Xu B，Zhu LH，Wu JG，et al. Pancreatic solid cystic desmoid tumor：case report and literature review [J]. World J Gastroenterol，2013，19（46）：8793-8798．
[13] Crago AM，Chmielecki J，Rosenberg M，et al. Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid type fibromatosis by whole-exome sequencing and genomic analysis [J]. Genes Chromosomes Cancer，2015，54（10）：606-615.
[14] Van Broekhoven DL，Verhoef C，Grunhagen DJ，et al. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis [J]. Ann Surg Oncol，2015， 22（5）：1464-1470．
[15] Vitellaro M，Sala P，Signoroni S，et al. Risk of desmoid tumours after open and laparoscopic colectomy in patients with familial adenomatous polyposis [J]. Br J Surg，2014，101（5）：558-565.
[16] Shields CJ，Winter DC，Kirwan WO，et al. Desmoid tumour [J]. Eur J Surg Oncol，2001，27（8）：701-706.
[17] Leithner A，Gapp M，Leithner K，et al. Margins in extra abdominal desmoid tumors：a comparative analysis [J]. J Surg Oncol，2004，86（3）：152-156.
[18] Bocale D，Rotelli MT，Cavallini A，et al. Anti-oestrogen therapy in the treatment of desmoid tumors：a systematic review [J]. Colorectal Dis，2011，13（12）：e388-e395.
[19] Teshima M，Iwae S，Hirayama Y，et al. Nonsteroidal anti-inflammatory drug treatment for desmoid tumor recurrence after surery [J]. Otolaryngol Head Neck Surg，2012， 147（5）：978-979.
[20] Janinis J，Patriki M，Vini L，et al. The pharmacological treatment of aggressive fibromatosis：a systematic review [J]. Ann Oncol，2003，14（2）：181-190.